Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jan;16(1 Suppl):S138-45.
doi: 10.1016/j.bbmt.2009.10.023. Epub 2009 Oct 24.

Relapse after allogeneic hematopoietic cell therapy

Marcel R M van den Brink  1 , David L Porter, Sergio Giralt, Sydney X Lu, Robert R Jenq, Alan Hanash, Michael R Bishop
Affiliations
Review

Relapse after allogeneic hematopoietic cell therapy

Marcel R M van den Brink et al. Biol Blood Marrow Transplant. 2010 Jan.

Abstract

Disease relapse remains a major cause of mortality following allogeneic hematopoietic cell transplantation (HCT). Over the past decade, our understanding of the biology underlying the graft-versus-tumor/leukemia (GVT) effect has increased greatly; however, several other factors affect the occurrence and outcome of relapse, including conditioning regimen, type of allograft, and the histology, status, and sensitivity to chemotherapy of the disease being treated. The mainstay of relapse treatment is donor lymphocyte infusion (DLI), but the efficacy of DLI is quite variable depending on disease histology and state. As such, there is a significant need for novel therapies and strategies for relapse following allogeneic HCT, particularly in patients for whom DLI is not an option. The National Cancer Institute is sponsoring an international workshop to address issues and research questions relative to the biology, natural history, prevention, and treatment of relapse following allogeneic HCT.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Causes of death following allogeneic hematopoietic cell transplantation as reported to the Center for International Blood and Marrow Transplant Research
Figure 2
Figure 2. Second Allogeneic Hematopoietic Cell Transplantation as reported to the Center for International Blood and Marrow Transplant Research (22)
Probability of overall survival after second transplantation. (A) Age ≤20 years, duration of remission >6 months; (B) age >20 years, duration of remission >6 months; (C) age ≤20 years, duration of remission ≤6 months; and (D) age >20 years, duration of remission ≤6 months 2.
See this image and copyright information in PMC

References

    1. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med. 1975;292:832–843. 292, 895–902. - PubMed
    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–1826. - PubMed
    1. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104:1550–1558. - PubMed
    1. Aoudjhane M, Labopin M, Gorin NC, et al. Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) Leukemia. 2005;19:2304–2312. - PubMed
    1. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112:4371–4383. - PubMed

Publication types

MeSH terms